Literature DB >> 32105344

Accuracy of colposcopy-directed biopsy vs dynamic spectral imaging directed biopsy in correctly identifying the grade of cervical dysplasia in women undergoing conization: A methodological study.

Berit Bargum Booth1,2,3, Lone Kjeld Petersen4,5, Jan Blaakaer4,6, Tonje Johansen7, Henrik Mertz7, Katja Dahl1, Pinar Bor2,3.   

Abstract

INTRODUCTION: Dynamic spectral imaging (DSI) colposcopy has previously been found to improve sensitivity of CIN2+ detection. The aim of this study was to compare the histological diagnosis of colposcopic-directed biopsies (CDB) with that of DSI-directed biopsies in women undergoing conization, using the histological diagnosis of the conization specimen as gold standard.
MATERIAL AND METHODS: Women referred for colposcopy were included in a prospective cohort study at Randers Regional Hospital, Denmark, from January 2016 to February 2019. All women had four cervical punch biopsies taken. The first biopsy was taken from the area that appeared most abnormal by conventional colposcopy (ie, CDB) and the second biopsy from the area that appeared most abnormal using the DSI map. An additional two biopsies were taken either from other visible lesions or as random biopsies. Biopsies were analyzed separately. If any biopsies revealed cervical dysplasia of such a degree that excisional treatment was recommended, the patient was referred for conization. Subsequently, we compared the histological diagnosis of CDB and DSI-directed biopsies with that of the cone biopsy.
RESULTS: A total of 573 women were enrolled, 170 of which underwent conization. In women with an adequate colposcopy and representative biopsies (n = 124) there was an overall agreement rate between the worst biopsy diagnosis (of any four) and the conization diagnosis in 95.2% (95% CI 89.8-98.2) of women. CDB diagnosis agreed with the cone diagnosis in 80.6% (95% CI 72.6-87.2) of women. DSI-directed biopsy agreed with the cone diagnosis in 83.9% (95% CI 76.2-89.9) of women. The difference in detection rate between the CDB and the DSI-directed biopsy was, however, not significant (P = .54). Taking four biopsies increases the detection rate of cervical dysplasia to 95.2%, which was a significant increase from both CDB alone (P = .0008) and DSI-directed biopsy alone (P = .0053).
CONCLUSIONS: We found no significant difference in the ability to identify the cervical dysplasia grade between CDB and DSI-directed biopsies. A higher detection rate of cervical dysplasia was achieved with four biopsies than with one CDB biopsy or one DSI-directed biopsy.
© 2020 Nordic Federation of Societies of Obstetrics and Gynecology (NFOG). Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  DYSIS; biopsy; cervical intraepithelial neoplasia; colposcopy; conization; diagnosis; precancerous conditions

Year:  2020        PMID: 32105344     DOI: 10.1111/aogs.13832

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  3 in total

1.  Can the dynamic spectral imaging (DSI) color map improve colposcopy examination for precancerous cervical lesions? A prospective evaluation of the DSI color map in a multi-biopsy clinical setting.

Authors:  Berit Bargum Booth; Lone Kjeld Petersen; Jan Blaakaer; Tonje Johansen; Henrik Mertz; Katja Dahl; Pinar Bor
Journal:  BMC Womens Health       Date:  2021-01-12       Impact factor: 2.809

2.  Dynamic Spectral Imaging Colposcopy Versus Regular Colposcopy in Women Referred With High-Grade Cytology: A Nonrandomized Prospective Study.

Authors:  Berit Bargum Booth; Lone Kjeld Petersen; Jan Blaakaer; Tonje Johansen; Henrik Mertz; Christina Blach Kristensen; Søren Lunde; Katja Dahl; Pinar Bor
Journal:  J Low Genit Tract Dis       Date:  2021-04-01       Impact factor: 3.842

3.  Can biopsies be omitted after normal colposcopy in women referred with low-grade cervical cytology? A prospective cohort study.

Authors:  Mette Mindedahl Jespersen; Berit Bargum Booth; Lone Kjeld Petersen
Journal:  BMC Womens Health       Date:  2021-11-19       Impact factor: 2.809

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.